Trial Profile

Randomized Phase II Trial of the Sequences of Anthracyline and Taxane in Locally Advanced Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Cyclophosphamide; Doxorubicin; Fluorouracil
Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms NeoSAMBA

Most Recent Events

12 Feb 2020 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.
12 Feb 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Apr 2020.
14 Aug 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com